Oncology News

HONOLULU — Researchers from Penn State Milton S. Hershey Medical Center found that diabetes and metabolic syndrome were independent risk factors for the development of hepatocellular carcinoma, according to data presented during a plenary session at ACG 2015.

Delcath Systems, Inc. announced that a global phase 2 trial is underway and the first patient has been treated using Chemosat, its investigational hepatic delivery system of melphalan for the treatment of intrahepatic cholangiocarcinoma and unresectable hepatocellular carcinoma.

Researchers found that tigatuzumab in combination with Nexavar was not effective in treating patients with advanced hepatocellular carcinoma, according to phase 2 clinical trial data published in the Journal of Hepatology.

CASI Pharmaceuticals, Inc. announced the European Union granted Orphan Drug Designation of an investigational oncology drug, ENMD-2076, for the treatment of hepatocellular carcinoma and fibrolamellar carcinoma, a rare type of HCC.

The European Medicines Agency has granted orphan drug designation to Can-Fite BioPharma Ltd.’s CF102, a potential drug to treat hepatocellular carcinoma, according to a press release.

October is Liver Awareness Month and Bayer Healthcare Pharmaceuticals is partnering with the American Liver Foundation for the second year to help raise awareness of liver cancer through the “Are You at Risk?” campaign, according to a press release.

In a prospective study, the presence of circulating tumor cells was found to be associated with a decreased overall survival in patients with cholangiocarcinoma, suggesting it may be a useful biomarker for tumor prediction.

Liver transplantation combined with chemotherapy provided long-term DFS in pediatric patients with advanced hepatoblastoma and hepatocellular carcinoma, according to the results of a retrospective analysis.

Nintedanib, a triple angiokinase inhibitor, was found to be safe for treating patients with hepatocellular carcinoma and mild or moderate liver impairment, according to data from a phase 1 trial presented at the European Society for Medical Oncology’s European Cancer Congress.

The FDA granted orphan drug designation to Blueprint Medicines drug candidate BLU-554 for the treatment of hepatocellular carcinoma, according to a press release.